SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 1999
Biotech HOLDRsSM Trust
Initial Depositor
(Exact name of registrant as specified in its charter)
Biotech HOLDRsSM Trust
[Issuer with respect to the receipts]
New York
(State or other jurisdiction of incorporation)
Commission File Number
Not applicable
(I.R.S. Employer Identification No.)
c/o The Bank of New York, as Trustee
101 Barclay Street, 22-W
New York, New York
(Address of principal executive offices and zip code)
Page 1 of 5 pages.
The Exhibit Index appears at Page 4.
<PAGE>
Item 5. Other Events
On January 20, 2000, Sepracor Inc. declared a two-for-one stock split
on its common stock, to be effected by means of a stock dividend to shareholders
of record on February 1, 2000. The shares of common stock began trading on a
split-adjusted basis on February 28, 2000. The share amount of Sepracor Inc.
represented by a round-lot of 100 Biotech HOLDRs is 6.
IDEC Pharmaceuticals Corporation effected a two-for-one stock split on
its common stock by means of a stock dividend. The shares of common stock began
trading on a split-adjusted basis on December 21, 1999. The share amount of IDEC
Pharmaceuticals Corporation represented by a round-lot of 100 Biotech HOLDRs is
4.
On January 5, 2000, Human Genome Sciences, Inc. declared a two-for-one
stock split on its common stock, to be effected by means of a stock dividend to
shareholders of record on January 14, 2000. The shares of common stock began
trading on a split-adjusted basis on January 31, 2000. The share amount of Human
Genome Sciences, Inc. represented by a round-lot of 100 Biotech HOLDRs is 4.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
(99) Biotech HOLDRsSM Trust Prospectus Supplement dated January
21, 2000 to Prospectus dated November 22, 1999.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
Date: March 3, 2000 By: /s/ Stephen G. Bodurtha
---------------------------
Name: Stephen G. Bodurtha
Title: Attorney-in-Fact
3
<PAGE>
EXHIBIT INDEX
Number and Description of Exhibit Sequential
- --------------------------------- Page Number
-----------
(99) Biotech HOLDRsSM Trust Prospectus Pg. 5
Supplement dated January 21, 1999 to
Prospectus dated November 22, 1999.
4
PROSPECTUS SUPPLEMENT
(To Prospectus dated November 22, 1999)
[LOGO]
BIOTECH HOLDERs
1,000,000,000 Depositary Receipts
Biotech HOLDRs(TM) Trust
This prospectus supplement amends and supplements certain information
contained in the accompanying prospectus dated November 22, 1999 relating to the
sale of up to 1,000,000,000 depositary receipts by Biotech HOLDRs SM Trust.
The share amounts specified in the table on page 9 of the accompanying
prospectus shall be replaced with the following:
Primary
Share Trading
Name of Company Ticker Amounts Market
--------------- ------ ------- -------
Amgen Inc. AMGN 46 NASDAQ
Genentech, Inc. DNA 22 NYSE
Biogen, Inc. BGEN 13 NASDAQ
Immunex Corporation IMNX 14 NASDAQ
PE Corp-PE Biosystems Group PEB 9 NYSE
MedImmune, Inc. MEDI 5 NASDAQ
Chiron Corporation CHIR 16 NASDAQ
Genzyme Corporation GENZ 7 NASDAQ
Gilead Sciences, Inc. GILD 4 NASDAQ
Sepracor Inc. (1) SEPR 3 NASDAQ
IDEC Pharmaceuticals Corporation(2) IDPH 4 NASDAQ
QLT Photo Therapeutics Inc. QLTI 5 NASDAQ
Millennium Pharmaceuticals, Inc. MLNM 3 NASDAQ
BioChem Pharma Inc. BCHE 9 NASDAQ
Affymetrix, Inc. AFFX 2 NASDAQ
Human Genome Sciences, Inc.(3) HGSI 2 NASDAQ
ICOS Corporation ICOS 4 NASDAQ
Enzon, Inc. ENZN 3 NASDAQ
Celera Genomics CRA 2 NYSE
Alkermes, Inc. ALKS 2 NASDAQ
- -------
(1) On January 20, 2000, Sepracor Inc. declared a two-for-one stock split on
its common stock, to be effected by means of a stock dividend to
shareholders of record on February 1, 2000. The shares of common stock will
begin trading on a split-adjusted basis on February 28, 2000. At such date,
the share amount of Sepracor Inc. represented by a round-lot of 100 Biotech
HOLDRs will be 6.
(2) IDEC Pharmaceuticals Corporation effected a two-for-one stock split on its
common stock by means of a stock dividend. The shares of common stock began
trading on a split-adjusted basis on December 21, 1999. The share amount of
IDEC Pharmaceuticals Corporation represented by a round-lot of 100 Biotech
HOLDRs is 4.
(3) On January 5, 2000, Human Genome Sciences, Inc. declared a two-for-one
stock split on its common stock, to be effected by means of a stock
dividend to shareholders of record on January 14, 2000. The shares of
common stock will begin trading on a split-adjusted basis on January 31,
2000. At such date, the share amount of Human Genome Sciences, Inc.
represented by a round-lot of 100 Biotech HOLDRs will be 4.
The stock prices in the tables set forth in Annex A of the accompanying
prospectus have not been and will not be, adjusted to account for any stock
splits.
The date of this prospectus supplement is January 21, 2000.
